Press Enter to search · ESC to close

Crypto

Gilead: Twice-Yearly Lenacapavir Shows Near Double the One-Year Persistence of Daily Oral F/TDF in HIV Prevention

Gilead reported that twice-yearly lenacapavir achieved 85.6% one-year persistence for HIV pre-exposure prophylaxis, nearly double that of daily oral F/TDF. No HIV infections occurred in the lenacapavir group during the 52-week study period, compared with one infection in the daily oral F/TDF group. Serious adverse events were uncommon and unrelated to treatment, with no discontinuations due to adverse events in the lenacapavir arm.

Share

Related News

Cointime share card
Long-press the image to save or share
Pitch us Community Feedback